The rapid growth of cancer cells is permitted by metabolic changes, notably increased aerobic glycolysis and increased glutaminolysis. Aerobic glycolysis is also evident in the hypertrophying myocytes in right ventricular hypertrophy (RVH), particularly in association with pulmonary arterial hypertension (PAH). It is unknown whether glutaminolysis occurs in the heart. We hypothesized that glutaminolysis occurs in RVH and assessed the precipitating factors, transcriptional mechanisms, and physiological consequences of this metabolic pathway. RVH was induced in two models, one with PAH (Monocrotaline-RVH) and the other without PAH (pulmonary artery banding, PAB-RVH). Despite similar RVH, ischemia as determined by reductions in RV VEGFα, coronary blood flow, and microvascular density was greater in Monocrotaline-RVH versus PAB-RVH. A sixfold increase in 14 C-glutamine metabolism occurred in Monocrotaline-RVH but not in PAB-RVH. In the RV working heart model, the glutamine antagonist 6-diazo-5-oxo-L-norleucine (DON) decreased glutaminolysis, caused a reciprocal increase in glucose oxidation, and elevated cardiac output. Consistent with the increased glutaminolysis in RVH, RV expressions of glutamine transporters (SLC1A5 and SLC7A5) and mitochondrial malic enzyme were elevated (Monocrotaline-RVH > PAB-RVH > control). Capillary rarefaction and glutamine transporter upregulation also occurred in RVH in patients with PAH. cMyc and Max, known to mediate transcriptional upregulation of glutaminolysis, were increased in Monocrotaline-RVH. In vivo, DON (0.5 mg/kg/day×3 weeks) restored pyruvate dehydrogenase activity, reduced RVH, and increased cardiac output (89±8, vs. 55±13 ml/min, p<0.05) and treadmill distance (194±71, vs. 36 ±7 m, p<0.05) in Monocrotaline-RVH. Glutaminolysis is induced in the RV in PAH by cMyc-Max, likely as a consequence of RV ischemia. Inhibition of glutaminolysis restores glucose oxidation and has a therapeutic benefit in vivo.
Introduction
A shift in glucose metabolism from glucose oxidation (GO) to aerobic glycolysis, the so-called Warburg effect [1] , and induction of glutaminolysis [2] are hallmarks of cancer metabolism. These two metabolic abnormalities often occur in tandem, perhaps because they can both be upregulated by the activation of proto-oncogene cMyc [2, 3] . These metabolic pathways promote rapid cell growth and proliferation and offer potential therapeutic targets for tumor regression [3, 4] . Intriguingly, aerobic glycolysis occurs in pulmonary vascular cells [5, 6] and hypertrophied right ventricular myocytes [7] in pulmonary arterial hypertension (PAH). This caused us to postulate that glutaminolysis might also be induced in the heart under conditions of right ventricular hypertrophy (RVH).
Although GO and fatty acid oxidation (FAO) are the classical metabolic pathways for cardiac adenosine triphosphate (ATP) generation in adult hearts [8] , metabolic plasticity occurs in the heart during development and with acquired pathologies, such as hypertrophy and ischemia. In PAH-associated RVH, a maladaptive metabolic switch to aerobic glycolysis [7] is mediated by increased expression and activity of pyruvate dehydrogenase kinase (PDK4), resulting in inhibition of pyruvate dehydrogenase (PDH) [9] . ATP production by this less efficient process is supported by increased glucose influx, mediated via upregulated expression of glucose transporter 1 (Glut1). This energetic response to pressure overload supports myocyte growth at the price of generation of increased lactic acid production, bioenergetic impairment and impaired RV function. PDK inhibitors, such as dichloroacetate, restore PDH activity and GO and improve RV function in experimental models of RVH [7, 10] .
The role of glutaminolysis in the heart is unknown. However, in cancer, glutamine can support cell metabolism by oxidation to CO 2 , yielding ATP [3] . Glutamine can also be hydrolysed to glutamate and subsequently converted to α-ketoglutarate (α-KG) in the mitochondria. α-KG can enter Krebs' cycle and replenish the metabolic intermediates, thereby supporting the biosynthetic demands for nicotinamide adenine dinucleotide phosphate and fatty acids during rapid cell growth. This replenishment of the metabolic intermediates is called anapleurosis. Glutaminolysis may also support cell growth by increasing nitrogen anabolism [3] .
There are similarities between aerobic glycolysis and glutaminolysis. For example, lactate generation is increased in glutaminolysis (in this case, via malic enzyme, Me) [11] . In addition, the high glutamine influx required by glutaminolysis requires upregulation of the glutamine transporters, SLC1A5 and SLC7A5 [3] , analogous to the upregulation of the Glut1 transporter in aerobic glycolysis [7, 10] .
Changes in glutamine and glutamate uptake have been noted in chronic ischemic heart disease [12, 13] . Based on studies using positron emission tomography, Knapp et al. suggested that glutamate utilization may be involved in metabolic adaptation in ischemic myocardium in patients with coronary artery disease [14] . Additional circumstantial evidence of cardiac glutaminolysis includes the observation of elevated serum glutamine levels during acute myocardial ischemia [15] and the activation of cMyc in left ventricular hypertrophy and ischemia [16] . However, to our knowledge glutaminolysis has never been directly measured in the heart nor are its consequences known.
We hypothesized that RV ischemia and cMyc activation in PAH-associated RVH initiate cardiac glutaminolysis. We speculated that glutaminolysis might contribute to the increased myocyte growth in RVH. We studied this in two rodent RVH models, one associated with PAH (Monocrotaline-RVH) and another in which RVH is induced by pulmonary artery banding (PAB). Despite identical severity of hypertrophy, Monocrotaline-RVH is maladaptive with more severe ischemia, autonomic remodeling, and RV dysfunction as compared to PAB-RVH [17] . Indeed in Monocrotaline-RVH, abnormalities of metabolic and adrenergic signaling extend to the left ventricle. The microvascular rarefaction in certain forms of RVH, such as Monocrotaline-RVH, may be conducive to glutaminolysis since it could promote ischemia. Because PAB-RVH has much less capillary rarefaction, it is an excellent comparator model [18] . A specific glutaminolysis inhibitor, 6-diazo-5-oxo-L-norleucine (DON), was used to determine the physiologic consequences of increased cardiac glutaminolysis. Results in rodent RVH are also tested in tissues from patients with PAH and RVH.
In this study, we provide an initial description of right ventricular glutaminolysis, propose a mechanism for its induction (ischemia-induced activation of cMyc), and demonstrate a novel reciprocal relationship between glutaminolysis and GO. Glutaminolysis is maladaptive, and inhibition of glutaminolysis has therapeutic promise in RVH.
Methods and materials
All authors have read and agreed to the manuscript as written.
Experimental protocols The University of Chicago Institutional Animal Care and Use Committee approved all rodent protocols. The institutional review board approved the use of autopsied human tissues for research. The demographics of the control, idiopathic PAH, and scleroderma PAH patients are in presented in the "Electronic supplementary material".
RVH models RVH models were created, as previously described, in male Sprague-Dawley rats (260-280 g) [7] : (1) PAB-RVH was induced by surgical placement of a 1.6 mm PA band. A median sternotomy was performed, and the PA was dissected free from the aorta and left atrium. A silk suture was placed around the PA, and a loose knot formed. A 16-gauge needle was inserted through the knot, parallel to the PA. The suture was tied tightly and the needle was withdrawn, creating a stenosis equal to the needle's diameter (~1.6 mm); and (2) Monocrotaline-RVH was induced by a single subcutaneous injection of monocrotaline (60 mg/kg, SC, Sigma, St. Louis, MO, USA). Endpoints were measured after 4 weeks. In additional cohorts, DON (0.5 mg/kg/day×3 weeks, Sigma) was injected intraperitoneally, beginning at 1 week after monocrotaline injection.
Echocardiography A Vevo 2100 (Visual Sonics, Toronto, Ontario, Canada) was used to assess pulmonary artery acceleration time (PAAT), right ventricular free wall (RVFW), stroke volume, tricuspid annular plane systolic excursion (TAPSE), and RV function, as previously described [10] . Transthoracic echocardiograms were performed on lightly anesthetized but spontaneously breathing rats (isoflurane 2.0 % in medical gas) [7, 10] . RVFW diastolic thickness was assessed by two-dimensional and M-mode echocardiography using right parasternal long-axis imaging views with the ultrasonic beam positioned perpendicularly to the wall in the proximal part of the mid-third of the RV.
TAPSE was measured as a marker of RV function. TAPSE was measured by placing the M-mode cursor through the lateral portion of the tricuspid annular plane in the apical four-chamber view and measuring systolic excursion.
Treadmill distance Exercise capacity was tested by measuring the maximal distance run on a motorized treadmill (Simplex II Instrument; Columbus Instruments, Columbus, OH, USA) as described [10] . The initial treadmill speed was 10 m/min and increased by 5 m/min every 5 min for 30 min or until the rat was fatigued. The treadmill distances in control versus the RVH model was measured 4 weeks after monocrotaline injection.
RVH RVH was measured postmortem as the ratio of RV/(LV + septum) weight.
Coronary flow measurement In RV Langendorff, the perfusate was collected from the coronary sinus. Total coronary flow was corrected for collection time and body weight.
Thermodilution cardiac output After anesthesia, the jugular vein and carotid artery were cannulated by the cut-down technique. A thermistor probe catheter (Physitemp Instruments, Inc., Clifton, NJ, USA) was inserted into the aorta via the carotid artery. A catheter was inserted into the right atrium via the jugular vein; 0.3 ml ice-cold saline was then quickly injected into the right atrium and a thermodilution curve (temperature vs. time) was recorded. PowerLab (ADInstruments Inc, Colorado Springs, CO, USA) was used for data acquisition. CO was then determined by calculating the area under the temperature curve.
Measurement of 14 C-glutamine or 14 C-glucose metabolism in the RV working heart model The RV working heart model was used to simultaneously measure metabolism and cardiac function, as previously described [7] . The heart was rapidly excised and subsequently mounted on an aortic perfusion cannula for about 10 min. The pulmonary veins, main PA, and superior vena cava were isolated and cannulated. The inferior vena cava was isolated and ligated. To initiate flow to the RV and left ventricle (LV), perfusate was delivered to the superior vena cava and left atria cannulae at constant preload (45 and 115 mmHg, respectively). Hearts worked against 80 mm Hg aortic afterload and 45 mm Hg PA afterload. Cardiac output (CO) and stroke work (SW) were measured with a Millar pressure-volume catheter (Millar, Houston, TX, USA).
Glutaminolysis and glucose oxidation were measured by perfusing hearts with Krebs-Henseleit buffer containing 2 mM [ 14 C]glutamine+5 mM glucose or 11 mM [
14 C]glucose, 0.5 mM lactate, 1.2 mM palmitate, 3 % albumin, and 100 U/ml insulin. The dose of 2 mM glutamine was selected based on concentrations commonly used in the culture medium for cardiac myocytes [19, 20] and in working heart perfusate solutions [21, 22] . The effects of DON on glutaminolysis, glucose oxidation, and cardiac function were evaluated by quantitative collection of 14 CO 2 at 10-min intervals after adding 5 DON to the perfusate.
A pressure-volume signal was continuously recorded at a sampling rate of 1,000/s using an MPVS-300 (ADInstruments Inc, Colorado Springs, CO, USA) coupled to a PowerLab8/30 converter (ADInstruments). CO and stroke volume were computed using pressure-volume analysis software (Labchart7.2; ADInstruments).
Cytosolic glutamine, malate, and lactate level were measured following the manufacturer's instructions (Abcam, Cambridge, MA, USA).
qRT-PCR RNA extraction and quantitative RT-PCR (qRT-PCR) was performed per the manufacturer's protocol (Applied Biosystems, Foster City, CA, USA). mRNA levels of cMyc, its partner Max, HIF-1α, vascular endothelial growth factor α (VEGFα), Glut1, hexokinase 1 (HK1), HK2, glutamine transporters SLC7A5 and SLC1A5, glutaminase, and mitochondrial and cytosolic malic enzyme (Me1 and Me2) were assessed by an ABI PRISM 7900HT PCR system (Applied Biosystems). mRNA expression was normalized to 18S mRNA.
Immunoblot Nuclear proteins from RV tissues were isolated following the manufacturer's instructions (Thermo Scientific, Rockford, IL, USA). Western blots were performed using standard procedures [7] .
Immunofluorescence Frozen sections were fixed in methanol, blocked with albumin (Sigma, St. Louis, MO, USA), and incubated with primary antibodies for 1 h at 25°C (mouse monoclonal anti-dystrophin, 1:400 dilution; rabbit polyclonal anticMyc and anti-SLC1A5 1:500 dilution, Abcam, Cambridge, MA, USA). Immunostaining was performed using standard procedures.
Capillary staining RV tissue microarray samples from patients with idiopathic PAH, patients with sclerodermaassociated PAH, and patients without PAH (control) (see "Electronic supplementary material" for clinical data) were stained for the endothelial marker CD31 and smooth muscle actin. RV sections from both rodent RVH models and control were stained with another endothelial marker, tomato lectin. Images were obtained with a Zeiss Axio Observer Z1 inverted microscope, and capillary densities were analyzed by using ImageJ (NIH, Bethesda, MD, USA).
Statistics and sample size Values were expressed as mean ± SEM. For comparisons between groups, ANOVA or unpaired Student's t-test was used as appropriate. For post hoc testing, Bonferroni's correction was used. P<0.05 was considered as statistically significant.
Results
RV/LV + septum ratio was similarly increased in PAB-RVH (0.51±0.02) and Monocrotaline-RVH (0.54±0.03) vs. control (0.26±0.01) (p<0.01).
RV working heart and metabolism In the presence of glutamine in the perfusate [22] , low rates of glutaminolysis were noted in control and PAB-RVH groups. Direct measurement of [ ; Fig. 1a ). In the absence of glutamine (with glucose as the only substrate), GO, measured as [ ; Fig. 1b ) as previously described [7] . Addition of glutamine reduced the rates of GO in control hearts. Conversely, in the presence of glutamine, DON significantly increased GO ). Consistent with the increased glutaminolysis being greatest in Monocrotaline-RVH, DON increased CO and SW in Monocrotaline-RVH (CO, 193±22 vs. 111±19 ml/min; SW, 27±2 320 vs. 15±3 mmHg ml; Fig. 1c, d ) without significantly altering hemodynamics in PAB-RVH . DON did cause an unexplained increase in CO in control hearts but did not change SW. Together these findings indicate that there is minimal glutaminolysis in control hearts and that glutaminolysis is markedly elevated in Monocrotaline-RVH. Glutaminolysis appears to be maladaptive since inhibiting glutaminolysis increases CO and SW in Monocrotaline-RVH.
Increased expression of cMyc-Max in RVH In Monocrotaline-RVH, there was a biventricular increase in mRNA expression of cMyc and Max (Fig. 2a) . In PAB-RVH, Max was not increased (Fig. 2a) . Increased cMyc was also seen in immunohistochemistry staining of the RV (Fig. 2b) . The results from immunostaining and an immunoblot performed on the nuclear extracts from RV myocytes confirmed that the cMyc was activated, which was evident as increased nuclear localization (Fig. 2b, c) . The success of the nuclear fractionation was confirmed by the presence of the nuclear protein topoisomerase 1 in the nuclear fraction (Fig. 2c) .
Increased expression of glutamine transporters in RVH In Monocrotaline-RVH, there was a biventricular increase in mRNA expression of glutamine transporters SLC1A5 and SLC7A5 ( Fig. 3a, b; Supplemental Fig. 1a) . In PAB-RVH, only SLC7A5 expression was increased and only in the RV (Fig. 3a) . Glutaminase expression was unaltered by either form of RVH (Supplemental Fig. 1b) . Interestingly, cytosolic malic enzyme (Me1) was reduced in Monocrotaline-RVH and elevated in PAB-RVH (Fig. 3b) , whereas mitochondrial malic enzyme (Me2) was increased only in Monocrotaline-RVH. Protein expression of SLC1A5 was significantly increased in Monocrotaline-RVH (Fig. 3c) . Consistent with the pattern of change in the expression of glutamine transporter genes and Me2, the RV tissue levels of glutamine, malate, and lactate increased more in Monocrotaline-RVH versus PAB-RVH (Fig. 4a) . Moreover, plasma glutamine and malate levels also increased significantly in Monocrotaline-RVH but not in PAB-RVH (Fig. 4b) .
Glycolytic genes, Glut1, and HK1 were increased in both RVH models, whereas HK2 was only increased in Monocrotaline-RVH (Supplemental Fig. 1c) . HIF-1α was also only increased in Monocrotaline-RVH but not in PAB-RVH (Supplemental Fig. 1d ). Protein expression of HIF-1∝ in the nuclei of RV myocytes was present in Monocrotaline-RVH, although this finding could not be reproduced in all experiments (data not shown).
Microvascular rarefaction Reduction in coronary flow and capillary rarefaction was noted in both models but was most severe in Monocrotaline-RVH (Fig. 5a-c) . Consistent with this, biventricular reduction in VEGFα mRNA was restricted to Monocrotaline-RVH (Fig. 5d) . Capillary rarefaction also occurred in PAH patients, particularly those with scleroderma PAH (Fig. 5e, f ; see demographics in Supplemental Table 1 ).
In vivo therapy with chronic DON Since glutaminolysis was primarily evident in Monocrotaline-RVH, we focused our in vivo studies of chronic DON on the Monocrotaline rat. DON reduced RVH in Monocrotaline rats as evidenced by the reduced RV/LV + septum ratio (0.43±0.04 vs. 0.60±0.02) and RVFW (0.53±0.04 vs. 1.00±0.13 mm; Fig. 6a, b) . DON increased CO and treadmill distance in Monocrotaline rats (CO, 89±8 vs. 55±13 ml/min; treadmill distance, 194±70 vs. 36±7 m; Fig. 6d, e) . DON reduced body weight in control but not in Monocrotaline rats (control, 412±10 vs. 528±12 g; Monocrotaline, 430±19 vs. 365±28 g; Supplemental Fig. 2a) . DON tended to reduce RVSP (51.2±6.0 to 39.3±2.4 mmHg, p=0.08; Supplemental Fig. 2c ) and, in a study with increased DON dosage, significantly increased PAAT, but only when given in high doses which had systemic toxicity in Monocrotaline-induced RVH (Supplemental Fig. 3c ). This suggests that DON not only improves cardiac function but also may have beneficial effects on the pulmonary vasculature. DON did significantly increase TAPSE in Monocrotaline rats (control, 1.12±0.16 vs. 1.81±0.16; Monocrotaline, 0.97±0.06 vs. 0.59±0.11 mm; Fig. 6c ). These findings indicate that inhibiting glutaminolysis is beneficial and suggest that DON's beneficial effects on CO and treadmill time are related primarily to effects on the RV. However, potential effects of DON on the pulmonary vasculature require further study. (Fig. 6f) . DON also reduced the expression of key mediators of glutaminolysis (cMyc, SLC1A5, SLC7A5, and Me2 mRNA; Fig. 7a-c) and glycolytic genes (Glut1 and HK1; Supplemental Fig. 2d, e) . Consistent with the acute ability of DON to increase GO in RVH (Fig. 1b) , chronic DON therapy restored PDH activity in Monocrotaline-RVH (Fig. 7d) . This suggests that the inhibition of glutaminolysis may exert its benefits by enhancing GO. DON therapy reduced the mRNA expression of VEGFα (Supplemental Fig. 2f ), suggesting that DON therapy is not able to correct ischemia in RVH. In PAH patients, immunostaining results confirmed that SLC1A5 proteins were increased in the RV, particularly in the RV myocytes plasma membrane (Fig. 8a ).
Discussion
The current study reveals that cardiac glutaminolysis is induced in the maladaptive RVH that accompanies Monocrotalineinduced PAH. DON-sensitive glutaminolysis is increased approximately sixfold in Monocrotaline-RVH, with a small DON-sensitive rate of glutaminolysis being evident in PAB-RVH. This difference in glutaminolysis between models likely reflects the greater ischemia seen in Monocrotaline-RVH (evident in the greater reduction in VEGFα expression, RV capillary density, and coronary blood flow). Monocrotaline-RVH's greater ischemic burden is associated with the activation of cMyc-Max signaling, evident by the upregulation of glutamine transporters. Although cMyc is upregulated in PAB-RVH, its binding partner Max is only increased in Monocrotaline-RVH (Fig. 2a) . Both capillary rarefaction and increased glutamine transporter expression were also seen in the RVs of patients with PAH-RVH (Fig. 5e, f) . Importantly, the inhibition of glutaminolysis by acute or chronic DON treatment in Monocrotaline-RVH improves GO and RV function (Figs. 1 and 7) , suggesting a new therapeutic strategy in treating RVH.
We demonstrate that the inhibition of glutaminolysis improves GO. This is reminiscent of the reciprocal relationship between GO and FAO (the Randle cycle), which we have previously exploited therapeutically in RVH [10] . In the case of the Randle cycle, it is the FAO metabolites (such as citrate) that inhibit GO while FAO inhibitors, such as trimetazidine, restore GO in RVH [10] . We speculate that glutaminolysisderived products similarly suppress GO. DON rapidly (<30 min) inhibits glutaminolysis and restores GO (Fig. 1) . Although the switch back to GO in the working heart model is too rapid to be transcriptionally mediated, there are additional transcriptionally mediated interactions that may be relevant to the ability of chronic DON therapy to restore PDH activity (Fig. 7) . Kaadige [23] . Inhibition of glutaminolysis with aminooxyacetate, which prevents conversion of glutamate to α-KG, restricts glucose uptake in pancreatic cancer cell lines [23] . They proposed that this mechanism coordinates glutamine and glucose utilization, serving as a "metabolic checkpoint that restricts cell growth when subthreshold levels of these essential nutrients are present" [23] . We have previously found that both PAB and Monocrotaline-RVH have a metabolic switch from GO to glycolysis [7] . Interestingly, PAB, a model of adaptive RVH [17, 18] , manifests several differences in glutamine metabolism as compared with Monocrotaline-RVH, a maladaptive model. Unlike in Monocrotaline-RVH, SLC1A5, Max, and Me2 mRNA are not increased in PAB-RVH. Consistent with this, glutaminolysis is quantitatively much less in PAB-RVH. Indeed the only evidence of a slight increase in glutaminolysis in PAB-RVH is the finding that DON does lower glutaminolysis levels significantly (albeit by a small absolute amount) (Fig. 1) .
The metabolic roles of Me1 and Me2 have not been fully resolved. Malate is an important Krebs' cycle intermediate and can be exported from the mitochondria to the cytosol. Both pyruvate carboxykinase and cytosolic NADP + -dependent Me1 support pyruvate cycling, which is a necessary step for glucosestimulated insulin secretion [24] . The increased Me1 in PAB-RVH may be helpful in pyruvate cycling so that more pyruvate influxes into the mitochondria, thereby assisting in ATP creation through Krebs' cycle. Conversely, in Monocrotaline-RVH, the reduced Me1 decreases the ability of pyruvate to influx into the mitochondria. Glutaminolysis-derived Me2 can also provide an alternative source of pyruvate when pyruvate flux from glycolysis is limited [25] . In the current study, chronic DON therapy reduced the expression of Me2 but not Me1 (Fig. 7c) . In pancreatic beta cells, Me1 knockdown decreases the flux of pyruvate derived from both glycolysis and glutamine-related pools through pyruvate carboxylase [24] . In contrast, Me2 knockdown affects only the flux of the pyruvate that derives from glutamate metabolism [24] . Further study will be required to determine which malate enzyme isoform is most relevant for cardiac glutaminolysis. The marked increase in expression of Me2 in Monocrotaline-RVH, which reverses with DON ( Fig. 3) , argues for an important role for this isoform in the metabolic phenotype of RVH (Fig. 8b) . The plasma and RV tissue levels of glutamine are increased in RVH (Figs. 4 and 6f) . The markedly increased expression of SLC1A5 and SLC7A5 in the RV in RVH suggests an increased glutamine uptake (Fig. 3) . This is consistent with the increased glutamine level in the RV tissues. Meanwhile, as shown in Figs. 4 and 6 , the levels of glutamate, malate, and lactate were all increased in RV tissues in the Monocrotaline model, suggesting increased glutaminolysis in RVH.
It is well known that cMyc is the key regulator for glutamine metabolism [26] . In the current study, it is apparent not only that cMyc activation is associated with an increase in RV glutamine metabolism but also that chronic administration of DON reduced cMyc and glutamine transporters' expression in the RV in rats with RVH. This suggests that there is a bidirectional positive feedback relationship between cMyc and glutaminolysis. This observation is consistent with that seen in human choriocarcinoma cells in which DON significantly reduced cMyc mRNA expression [27] .
In cancer, cMyc orchestrates the transcriptional upregulation of glutaminolysis [26, 28] . In cancer cells, cMyc cooperates with HIF-1α by binding to E-boxes of glycolytic genes, thereby promoting glycolysis. cMyc is also essential for glutaminolysis by regulating SLC1A5 and glutaminase [2] . cMyc is essential for vasculogenesis and angiogenesis and is required for the expression of VEGFα [29] . Activation of cMyc in the heart has been reported to occur as a result of ischemia in LVH [16] . It is likely that cMyc activation in RVH reflects capillary rarefaction and RV ischemia (Fig. 5) . The relationship between ischemia/hypoxia, VEGFα, and cMyc in the heart requires further investigation.
The purpose of glutaminolysis in RVH remains uncertain. Extrapolation from cancer metabolism would suggest that glutaminolysis supports rapid cell growth (myocyte hypertrophy) in RVH. The consequences of RV glutaminolysis is largely negative, which is evident from the fact that inhibition of glutaminolysis with DON in Monocrotaline-RVH restores GO and improves RV function ex vivo (Fig. 1) while regressing RVH and increasing exercise capacity in vivo (Fig. 6) .
The importance of glutaminolysis would be missed if one studied only normal hearts. A recent study by Lauzier et al. using the working heart preparation found that overall glutamine had little effect on the contractile function. We show that the pathway is only induced in RVH. Thus, consistent with the findings of Lauzier et al. [30] , we conclude that there is little glutaminolysis under control condition (Fig. 1) . However, in RVH, increased glutaminolysis impairs cardiac output and shortens treadmill distance. By reducing glutaminolysis with chronic DON therapy, RVH was reduced and cardiac output and treadmill capacity were improved in RVH.
Limitations
PAB is considered to have less ischemia-inducing potential than Monocrotaline because of the relative paucity of the microvascular disease in this model. However, PAB may cause a supply-demand mismatch in perfusion that could evoke modest ischemia. The observation that cMyc expression is increased and capillary density is decreased in the PAB-RV while glutaminolysis remains low raises questions as to the relatedness of these observations in PAB-RVH. However, cMyc's obligatory binding partner, Max, is not elevated in PAB (Fig. 2a) , which may reduce cMyc/Max signaling. In addition, the reduction in capillary density in PAB is significantly less than in Monocrotaline-RVH. These observations suggest less severe ischemia and perhaps milder activation of glutaminolysis in PAB-RVH compared to Monocrotaline-RVH. The finding that DON does reduce glutaminolysis (Fig. 1a) and increase glucose oxidation (Fig. 1b) in PAB-RVH suggests mild induction of glutaminolysis in this condition.
There may be unknown off-target effects of DON, which might complicate the interpretation of our findings. However, the careful measurement of glutaminolysis does verify that DON did indeed inhibit glutaminolysis in our studies. DON has dose-limiting neurotoxicity and gastrointestinal toxicity [26] . Consistent with this, a higher DON dose (1 mg/kg/day×10-days) regressed Monocrotaline-RVH and pulmonary vascular disease but caused severe weight loss and weakness (Supplemental Fig. 3) . Future studies will need to explore other potential glutaminolysis inhibitors that may have a greater therapeutic window. In Monocrotaline-RVH, abnormalities in the expression of VEGFα, Glut1, SLC7A5, Me2, cMyc, and Max extended to the LV (Figs. 2 and 3; Supplemental Fig. 1 ). Further study is required to definitively establish whether glutaminolysis also occurs in the LV in maladaptive RVH. However, the observation that the LV is involved in a shift to glutaminolysis in Monocrotaline-induced PAH is not entirely unexpected. We recently found that adrenergic remodeling occurs in the LV in this model, albeit to a lesser extent than in the RV [17] . While we did not prove that the increase in SLC7A5 and cMyc resulted to microvascular rarefaction in the LV, this interpretation is supported by the reduced LV expression of VEGFα in the LV (Fig. 5d ).
In the current study, we choose Monocrotaline-RVH as a maladaptive (heart failure plus PAH model) combined with PAH and RVH. As a comparison, PAB-RVH does not develop lung disease, PAH, or heart failure [31] . Glutamine metabolism could also be accessed in another RVH model such as chronic hypoxia + SU-5416 (a VEGF receptor inhibitor).
In the RV working heart model, we used 2 mM glutamine in the perfusate. While this is likely higher than that seen in vivo (Fig. 4b) , it is a commonly used dose in the literature and had no acute adverse effect on cardiac function (Supplemental Fig. 4) .
Although the glutaminolysis pathway is an intriguing target for new PAH therapeutics, it must be acknowledged that DON was abandoned as a cancer therapeutic because of toxicity. There are other drugs that have effects on glutaminolysis. For example, phenylbutyrate (also called ammonaps) is an FDAapproved agent for the treatment of hyperammonemia in congenital urea cycle disorders and has shown and can significantly deplete plasma glutamine [32] . In vitro treatment of lung cancer cells with L-g-glutamyl-p-nitroanilide (an inhibitor of SLC1A5) decreased cancer cell growth and viability by inhibiting SLC1A5 and lowering glutamine levels [33] . Further studies of these and other modulators of glutaminolysis are indicated in PAH-RVH models. Direct cMyc inhibition, using small- Proposed mechanism of glutaminolysis in RVH. RV ischemia and capillary rarefaction activate cMyc and Max, which increases glutamine uptake and production of α-ketoglutarate (α-KG). α-KG enters Krebs' cycle, leading to production of malate. Krebs' cycle-derived malate generates cytosolic pyruvate, which is converted by lactate dehydrogenase A (LDHA) to lactate. In conditions of high glutaminolysis, GO is inhibited molecule inhibitors such as 10058-F4 [34] , may be an alternative means of reducing glutaminolysis. HIF-1α mRNA levels were increased in Monocrotaline-RVH (Supplemental Fig. 1d ). However, there was nuclear translocation of HIF-1α, consistent with its activation, in the limited number of Monocrotaline-RVH specimens assessed (data not shown).
Conclusions
To our knowledge, this is the first demonstration of cardiac glutaminolysis. The metabolic parallels between RVH and cancer are now expanded to include glutaminolysis, as well as aerobic glycolysis (Fig. 8b) . Inhibition of glutaminolysis has potential as a metabolic therapy targeting the right ventricle.
